問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Surgery

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間：2023-09-19

吳教恩
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

107Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳教恩

List

132Cases

2014-06-01 - 2017-12-31

Phase III

A randomized, double-blinded, placebo controlled, multicentre phase III study to assess the efficacy and safety of olaparib (AZD2281) in combination with paclitaxel, compared to placebo in combination with paclitaxel, in Asian patients with advanced gastric cancer (including the gastro-oesophageal junction) who have progressed following first line therapy

  • Condition/Disease

    advanced gastric cancer

  • Test Drug

    Olaparib

Participate Sites
5Sites

Terminated5Sites

2019-05-01 - 2026-12-31

Phase I/II

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    BA3011

Participate Sites
4Sites

Recruiting4Sites

2019-10-01 - 2023-01-13

Phase II

A phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prior standard therapy

  • Condition/Disease

    Gastric Cancer / GastroEsophageal Cancer

  • Test Drug

    Bavituximab

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2024-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-03-02 - 2023-02-09

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2023-04-30 - 2026-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2022-10-01 - 2024-12-12

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-01-05 - 2026-01-06

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-04-01 - 2028-12-31

Phase I/II

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  • Condition/Disease

    c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  • Test Drug

    APL-101

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-11-01 - 2026-06-30

Phase III

Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)

  • Condition/Disease

    Advanced/Metastatic Gastroesophageal Adenocarcinoma

  • Test Drug

    吉舒達注射劑R/Keytruda injectionR樂衛瑪膠囊R/ Lenvima capsuleR

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

1 9 10 11 12 13 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB